451 related articles for article (PubMed ID: 27415753)
21. [Grading of prostate cancer].
Kristiansen G; Roth W; Helpap B
Pathologe; 2016 Jul; 37(4):352-4. PubMed ID: 27393141
[TBL] [Abstract][Full Text] [Related]
22. The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies.
Billis A; Guimaraes MS; Freitas LL; Meirelles L; Magna LA; Ferreira U
J Urol; 2008 Aug; 180(2):548-52; discussion 552-3. PubMed ID: 18550106
[TBL] [Abstract][Full Text] [Related]
23. Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy.
Faraj SF; Bezerra SM; Yousefi K; Fedor H; Glavaris S; Han M; Partin AW; Humphreys E; Tosoian J; Johnson MH; Davicioni E; Trock BJ; Schaeffer EM; Ross AE; Netto GJ
PLoS One; 2016; 11(1):e0146189. PubMed ID: 26731672
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up.
Grogan J; Gupta R; Mahon KL; Stricker PD; Haynes AM; Delprado W; Turner J; Horvath LG; Kench JG
BJU Int; 2017 Nov; 120(5):651-658. PubMed ID: 28371244
[TBL] [Abstract][Full Text] [Related]
25. Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system.
Dong F; Wang C; Farris AB; Wu S; Lee H; Olumi AF; McDougal WS; Young RH; Wu CL
Am J Surg Pathol; 2012 Jun; 36(6):838-43. PubMed ID: 22592143
[TBL] [Abstract][Full Text] [Related]
26. Contemporary Gleason grading and novel Grade Groups in clinical practice.
Magi-Galluzzi C; Montironi R; Epstein JI
Curr Opin Urol; 2016 Sep; 26(5):488-92. PubMed ID: 27308734
[TBL] [Abstract][Full Text] [Related]
27. Gleason score 3 + 4=7 prostate cancer with minimal quantity of gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen.
Huang CC; Kong MX; Zhou M; Rosenkrantz AB; Taneja SS; Melamed J; Deng FM
Am J Surg Pathol; 2014 Aug; 38(8):1096-101. PubMed ID: 24832163
[TBL] [Abstract][Full Text] [Related]
28. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
[TBL] [Abstract][Full Text] [Related]
29. Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma.
Montironi R; Cimadamore A; Gasparrini S; Mazzucchelli R; Santoni M; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M
Expert Rev Anticancer Ther; 2018 Jul; 18(7):685-693. PubMed ID: 29699428
[TBL] [Abstract][Full Text] [Related]
30. Gleason and Fuhrman no longer make the grade.
Delahunt B; Egevad L; Samaratunga H; Martignoni G; Nacey JN; Srigley JR
Histopathology; 2016 Mar; 68(4):475-81. PubMed ID: 26266664
[TBL] [Abstract][Full Text] [Related]
31. The reasons behind variation in Gleason grading of prostatic biopsies: areas of agreement and misconception among 266 European pathologists.
Berney DM; Algaba F; Camparo P; Compérat E; Griffiths D; Kristiansen G; Lopez-Beltran A; Montironi R; Varma M; Egevad L
Histopathology; 2014 Feb; 64(3):405-11. PubMed ID: 24102975
[TBL] [Abstract][Full Text] [Related]
32. The impact of the 2005 International Society of Urological Pathology (ISUP) consensus on Gleason grading in contemporary practice.
Zareba P; Zhang J; Yilmaz A; Trpkov K
Histopathology; 2009 Oct; 55(4):384-91. PubMed ID: 19817888
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups.
Offermann A; Hohensteiner S; Kuempers C; Ribbat-Idel J; Schneider F; Becker F; Hupe MC; Duensing S; Merseburger AS; Kirfel J; Reischl M; Lubczyk V; Kuefer R; Perner S
Front Med (Lausanne); 2017; 4():157. PubMed ID: 29034236
[TBL] [Abstract][Full Text] [Related]
34. Standardization of Gleason grading among 337 European pathologists.
Egevad L; Ahmad AS; Algaba F; Berney DM; Boccon-Gibod L; Compérat E; Evans AJ; Griffiths D; Grobholz R; Kristiansen G; Langner C; Lopez-Beltran A; Montironi R; Moss S; Oliveira P; Vainer B; Varma M; Camparo P
Histopathology; 2013 Jan; 62(2):247-56. PubMed ID: 23240715
[TBL] [Abstract][Full Text] [Related]
35. Active surveillance as a therapeutic option for patients with low-risk prostate cancer according to the 2014 International Society of Urological Pathology grading system: a review.
Helpap B; Gevensleben H
Scand J Urol; 2017 Feb; 51(1):1-4. PubMed ID: 27967297
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Utility of the Gleason Grading System Revisions and Histopathological Factors Beyond Gleason Grade.
Zelic R; Giunchi F; Fridfeldt J; Carlsson J; Davidsson S; Lianas L; Mascia C; Zugna D; Molinaro L; Vincent PH; Zanetti G; Andrén O; Richiardi L; Akre O; Fiorentino M; Pettersson A
Clin Epidemiol; 2022; 14():59-70. PubMed ID: 35082531
[TBL] [Abstract][Full Text] [Related]
37. An update of the Gleason grading system.
Epstein JI
J Urol; 2010 Feb; 183(2):433-40. PubMed ID: 20006878
[TBL] [Abstract][Full Text] [Related]
38. Prostate cancer grading in 2018: limitations, implementations, cribriform morphology, and biological markers.
Montironi R; Cimadamore A; Cheng L; Lopez-Beltran A; Scarpelli M
Int J Biol Markers; 2018 Nov; 33(4):331-334. PubMed ID: 29945478
[TBL] [Abstract][Full Text] [Related]
39. Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations.
Egevad L; Delahunt B; Kristiansen G; Samaratunga H; Varma M
Pathology; 2018 Jan; 50(1):60-73. PubMed ID: 29199015
[TBL] [Abstract][Full Text] [Related]
40. Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?
Montironi R; Cheng L; Cimadamore A; Mazzucchelli R; Scarpelli M; Santoni M; Massari F; Lopez-Beltran A
Transl Androl Urol; 2021 Mar; 10(3):1530-1540. PubMed ID: 33850787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
